Vericel NASDAQ: VCEL
Vericel Corporation, formerly Aastrom Biosciences, Inc. is a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions - dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues
Name | Vericel |
Ticker | VCEL |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Gene Editing - Cell Therapies |
Price | 41.23 |
52W Low/High | 7.25 / 41.23 |
Market cap | 1.9 B |
1Y Total Return |
145.12%
Strong |
1Y Volatility |
69.21%
More Risk |
Vericel Corporation, formerly Aastrom Biosciences, Inc. is a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions - dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues
Details
Ticker | VCEL |
Name | Vericel |
ISIN | US92346J1088 |
CUSIP | 92346J108 |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Gene Editing - Cell Therapies |
Country | USA |
Currency | U.S. Dollar |
Share as of 1/22/21
Close Price | 41.23 |
52W Low/High | 7.25 / 41.23 |
Market cap | 1.9 B |
1Y Total Return |
145.12%
Strong |
1Y Volatility |
69.21%
More Risk |
Beta | 1.30 |
PE (trailing) |
2,061.50
High |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | 0.1% |
Cash from Op. / Cur. Liabilities | 0.44 |
Diluted Earnings / Share | 0.02 |
ROE | 0.1% |
ROIC | 0.2% |
Price / Revenue | 16.5 |
Price / Book | 17.0 |
Price / CF | 207.9 |
Current Ratio | 5.9 |
Cur.Liabilities / Tot.Liabilities | 0.5 |
Financial Leverage | 0.24 |
in Mils USD |
rolling-year up to September
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
118
|
110
|
83
|
57
|
53
|
50
|
|
Gross Profit |
79
|
74
|
51
|
28
|
25
|
24
|
|
R&D |
13
|
30
|
14
|
14
|
18
|
17
|
|
EBITDA |
6
|
-10
|
-10
|
-21
|
-16
|
-12
|
|
Operating Income |
-1
|
-14
|
-9
|
-22
|
-18
|
-14
|
|
Net Income exc. Extra |
0
|
-
|
-
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
47
|
47
|
43
|
34
|
23
|
24
|
|
EPS exc. Extra |
0.02
|
-0.31
|
-0.33
|
-0.88
|
-1.12
|
-0.02
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
158
|
138
|
124
|
40
|
28
|
36
|
|
Cash, Eq & Invt ShortTerm |
86
|
75
|
98
|
15
|
9
|
19
|
|
Total Current Assets |
125
|
105
|
119
|
36
|
21
|
29
|
|
Total Non-Current Assets |
32
|
33
|
5
|
4
|
7
|
7
|
|
Intangibles |
0
|
0
|
0
|
0
|
3
|
3
|
|
Total Liabilities |
43
|
41
|
30
|
24
|
17
|
9
|
|
Total Current Liabilities |
21
|
15
|
15
|
15
|
15
|
9
|
|
Long Term Debt |
22
|
25
|
15
|
9
|
1
|
0
|
|
Shareholder equity |
115
|
97
|
94
|
17
|
11
|
26
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
9
|
-8
|
-2
|
-23
|
-15
|
-16
|
|
Depreciation |
6
|
3
|
2
|
2
|
2
|
1
|
|
Cash from Investing |
-6
|
5
|
-47
|
-1
|
-1
|
-3
|
|
Capex |
2
|
3
|
3
|
1
|
1
|
3
|
|
Cash from Financing |
4
|
-13
|
87
|
31
|
6
|
0
|
|
Stock Issued |
4
|
5
|
81
|
27
|
0
|
0
|
|
Debt (LT) Issued |
0
|
-18
|
7
|
4
|
6
|
0
|
|
Free Cash Flow |
-1
|
-26
|
-17
|
-33
|
-13
|
-30
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
0.1%
|
-
|
-
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
5.9
|
6.9
|
8.0
|
2.5
|
1.4
|
3.1
|
|
Financial Leverage D/E |
0.24
|
0.29
|
0.18
|
0.59
|
0.49
|
0.00
|
|
Return on Capital Avg |
0.2%
|
-19.1%
|
-34.7%
|
-322.3%
|
-313.1%
|
-338.3%
|
|
Return on Shareholder Equity |
0.1%
|
-
|
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available